From: A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China
Direct costs
Indirect costs
Total costs
pre-PP1M (¥)
17,457±17,414
15,967±10,128
33,095±21,984
Post-PP1M (¥)
23,030±8648
10,279±11,878
33,309±15,254
Difference
31.92
-35.62%
0.64%
P
< 0.01
0.25